Michel Tulliez

4.1k total citations · 1 hit paper
74 papers, 2.4k citations indexed

About

Michel Tulliez is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Michel Tulliez has authored 74 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Hematology, 44 papers in Genetics and 23 papers in Rheumatology. Recurrent topics in Michel Tulliez's work include Chronic Myeloid Leukemia Treatments (31 papers), Chronic Lymphocytic Leukemia Research (29 papers) and Eosinophilic Disorders and Syndromes (20 papers). Michel Tulliez is often cited by papers focused on Chronic Myeloid Leukemia Treatments (31 papers), Chronic Lymphocytic Leukemia Research (29 papers) and Eosinophilic Disorders and Syndromes (20 papers). Michel Tulliez collaborates with scholars based in France, United States and Italy. Michel Tulliez's co-authors include François Guilhot, Laurence Legros, William Vainchenker, Delphine Réa, François‐Xavier Mahon, Martine Gardembas, Bruno Varet, Stéphane Giraudier, Gabriel Étienne and Jean‐Michel Pignon and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Michel Tulliez

73 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia

2016 315 citations Gabriel Étienne, Joëlle Guilhot et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michel Tulliez France	24	1.6k	1.2k	789	381	312	74	2.4k
Eeva Juvonen Finland	30	1.6k 1.0×	1.1k 0.9×	242 0.3×	524 1.4×	619 2.0×	83	2.8k
Pietro Pioltelli Italy	23	969 0.6×	778 0.6×	326 0.4×	195 0.5×	319 1.0×	80	2.0k
Edoardo Rossi Italy	25	856 0.5×	526 0.4×	528 0.7×	187 0.5×	155 0.5×	58	2.0k
Nigel Westwood United Kingdom	21	913 0.6×	862 0.7×	223 0.3×	767 2.0×	480 1.5×	68	2.2k
Christophe Marzac France	19	1.7k 1.1×	538 0.4×	267 0.3×	516 1.4×	366 1.2×	58	2.5k
B. Grosbois France	26	1.2k 0.8×	780 0.6×	275 0.3×	1.3k 3.5×	636 2.0×	118	2.6k
Rita Rizzi Italy	21	545 0.3×	337 0.3×	295 0.4×	537 1.4×	506 1.6×	74	1.7k
Steven Fruchtman United States	20	1.1k 0.7×	1.1k 0.9×	408 0.5×	528 1.4×	133 0.4×	71	1.8k
Norifumi Tsukamoto Japan	25	826 0.5×	561 0.5×	244 0.3×	381 1.0×	433 1.4×	139	2.1k
Shin Fujisawa Japan	27	1.1k 0.7×	561 0.5×	186 0.2×	380 1.0×	572 1.8×	182	2.2k

Countries citing papers authored by Michel Tulliez

Since Specialization

Citations

This map shows the geographic impact of Michel Tulliez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michel Tulliez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michel Tulliez more than expected).

Fields of papers citing papers by Michel Tulliez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michel Tulliez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michel Tulliez. The network helps show where Michel Tulliez may publish in the future.

Co-authorship network of co-authors of Michel Tulliez

This figure shows the co-authorship network connecting the top 25 collaborators of Michel Tulliez. A scholar is included among the top collaborators of Michel Tulliez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michel Tulliez. Michel Tulliez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Réa, Delphine, Shanti Amé, Aude Charbonnier, et al.. (2016). Recommandations 2015 du France Intergroupe des Leucémies Myéloïdes Chroniques pour la gestion du risque d’événements cardiovasculaires sous nilotinib au cours de la leucémie myéloïde chronique. Bulletin du Cancer. 103(2). 180–189. 6 indexed citations

Réa, Delphine, Gabriel Étienne, Franck E. Nicolini, et al.. (2012). First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia. Leukemia. 26(10). 2254–2259. 30 indexed citations

Étienne, Gabriel, B. Milpied, Delphine Réa, et al.. (2010). Recommandations du groupe Fi-LMC pour la gestion des effets indésirables du traitement par nilotinib (Tasigna®) au cours de la leucémie myéloïde chronique. Bulletin du Cancer. 97(8). 997–1009. 15 indexed citations

Nicolini, Franck E., François‐Xavier Mahon, Joëlle Guilhot, et al.. (2009). A phase III study exploring various doses of imatinib (IM) or IM in combination for newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML) patients (pts): Results of an interim analysis of the SPIRIT trial of French CML group. Journal of Clinical Oncology. 27(15_suppl). 7058–7058. 1 indexed citations

Zetterberg, Eva, Alessandro M. Vannucchi, Anna Ritá Migliaccio, et al.. (2007). Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows. Haematologica. 92(5). 597–604. 30 indexed citations

Nicolini, Franck E., Emmanuel Bachy, Sélim Corm, et al.. (2006). Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation.. Blood. 108(11). 2190–2190. 1 indexed citations

Komura, Emiko, Hédia Chagraoui, Benoı̂t Blanchet, et al.. (2003). Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression. Experimental Hematology. 31(7). 622–630. 43 indexed citations

Maury, Sébastien, Hélène Jouault, Mathieu Kuentz, et al.. (2001). CHIMERISM ANALYSIS BY LINEAGE-SPECIFIC FLUORESCENT POLYMERASE CHAIN REACTION IN SECONDARY GRAFT FAILURE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION. Transplantation. 71(3). 374–380. 8 indexed citations

Tonetti, Carole, et al.. (2000). Methylenetetrahydrofolate reductase deficiency in four siblings: A clinical, biochemical, and molecular study of the family. American Journal of Medical Genetics. 91(5). 363–367. 8 indexed citations

10.

Zittoun, J, Carole Tonetti, Dominique Bories, Jean‐Michel Pignon, & Michel Tulliez. (1998). Plasma homocysteine levels related to interactions between folate status and methylenetetrahydrofolate reductase: A study in 52 healthy subjects. Metabolism. 47(11). 1413–1418. 34 indexed citations

11.

Bertrand, Vincent, Rosine Guimbaud, Philippe Sogni, et al.. (1998). Effects of murine recombinant interleukin-10 on the inflammatory disease of rats transgenic for HLA-B27 and human beta 2-microglobulin.. PubMed. 9(2). 161–70. 26 indexed citations

12.

Villeval, Jean‐Luc, Karine Cohen-Solal, William Vainchenker, et al.. (1997). Myélofibrose par excès de thrombopoïétine. médecine/sciences. 13(8-9). 1053–1053. 1 indexed citations

13.

Louache, Fawzia, A Henri, Ali Bettaı̈eb, et al.. (1992). Role of human immunodeficiency virus replication in defective in vitro growth of hematopoietic progenitors. Blood. 80(12). 2991–2999. 74 indexed citations

14.

Fajac, Isabelle, et al.. (1992). Pulmonary Hodgkin's Disease in HIV-Infected Patient. CHEST Journal. 102(6). 1913–1914. 4 indexed citations

15.

Lotz, Jean‐Pierre, D. Machover, Benoı̂t Malassagne, et al.. (1991). Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors.. Journal of Clinical Oncology. 9(10). 1860–1870. 31 indexed citations

16.

Valla, Dominique, Nicole Casadevall, Marie‐Geneviève Huisse, et al.. (1988). Etiology of portal vein thrombosis in adults. Gastroenterology. 94(4). 1063–1069. 42 indexed citations

17.

Levy, Ron, et al.. (1978). [Myocardial infarction after vincristine treatment (author's transl)].. PubMed. 7(30). 2657–2657. 4 indexed citations

18.

Tulliez, Michel. (1976). [Bone marrow's histopathology in tuberculosis of the hematopoietic organs (author's transl)].. PubMed. 24(10). 699–411. 1 indexed citations

19.

Tulliez, Michel, et al.. (1974). Preleukaemic Abnormal Myelopoiesis Induced by Chlorambucil: A Case Study. Scandinavian Journal of Haematology. 13(3). 179–183. 22 indexed citations

20.

Touraine, R, J. Revuz, & Michel Tulliez. (1972). Psoriasis and Hydroxyurea. British Journal of Dermatology. 86(1). 102–102. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact